当前位置: X-MOL 学术Expert Rev. Clin. Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease.
Expert Review of Clinical Immunology ( IF 3.9 ) Pub Date : 2020-01-17 , DOI: 10.1080/1744666x.2019.1697678
Alvise Berti 1, 2 , Sara Boukhlal 3 , Matthieu Groh 4 , Divi Cornec 3
Affiliation  

Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) usually occurs in patients with late-onset asthma and sustained peripheral blood eosinophilia and classically presents with a clinical multifaceted spectrum of manifestations, which may vary at the different stages of the natural history of the disease.Areas covered: We reviewed EGPA clinical presentation, focusing on clinical manifestations at three different phases of the disease: 1/before the development of overt vasculitis, 2/at vasculitis diagnosis and 3/during the long-term follow-up. An update on current classification criteria and recent therapeutic advances has been provided as well.Expert opinion: Asthma, chronic rhinosinusitis and blood eosinophilia could anticipate the overt vasculitis for years. An atopic background may be present in a subset of patients (25-30%), while ANCA presence varies between 10 and 40%. Systemic vasculitis rapidly occurs and clinical features demonstrating vasculitis processes (neuropathy, purpura, scleritis, alveolar hemorrhage and glomerulonephritis) develop along with systemic symptoms (50%). After vasculitis resolution, asthma remains severe in up to 50% of patients and incidence of isolated-asthma and rhinosinus exacerbations remains constantly high. Different sets of classification criteria have been published so far, and DCVAS diagnostic criteria will be presented soon. Interleukin-5 blockers seem to be promising to control the disease and to spare corticosteroids.

中文翻译:

嗜酸性肉芽肿伴多血管炎:疾病不同阶段的多方面临床表现。

简介:嗜酸性肉芽肿伴多血管炎 (EGPA) 通常发生在迟发性哮喘和持续外周血嗜酸性粒细胞增多的患者中,并且典型地表现为临床多方面的表现,在疾病自然病程的不同阶段可能会有所不同。涵盖:我们回顾了 EGPA 的临床表现,重点关注疾病三个不同阶段的临床表现:1/发生明显血管炎之前,2/血管炎诊断时和 3/长期随访期间。还提供了当前分类标准的更新和最近的治疗进展。 专家意见:哮喘、慢性鼻窦炎和血嗜酸性粒细胞增多可能预示着明显的血管炎多年。一部分患者(25-30%)可能存在特应性背景,而 ANCA 的存在在 10% 到 40% 之间变化。系统性血管炎迅速发生,显示血管炎过程(神经病变、紫癜、巩膜炎、肺泡出血和肾小球肾炎)的临床特征与全身症状一起发展(50%)。血管炎消退后,高达 50% 的患者哮喘仍然严重,孤立性哮喘和鼻窦炎发作的发生率仍然很高。到目前为止,已经发布了不同的分类标准,DCVAS 诊断标准将很快推出。白细胞介素 5 阻滞剂似乎有望控制疾病并避免使用皮质类固醇。肺泡出血和肾小球肾炎)伴随全身症状出现(50%)。血管炎消退后,高达 50% 的患者哮喘仍然严重,孤立性哮喘和鼻窦炎发作的发生率仍然很高。到目前为止,已经发布了不同的分类标准,DCVAS 诊断标准将很快推出。白细胞介素 5 阻滞剂似乎有望控制疾病并避免使用皮质类固醇。肺泡出血和肾小球肾炎)伴随全身症状出现(50%)。血管炎消退后,高达 50% 的患者哮喘仍然严重,孤立性哮喘和鼻窦炎发作的发生率仍然很高。到目前为止,已经发布了不同的分类标准,DCVAS 诊断标准将很快推出。白细胞介素 5 阻滞剂似乎有望控制疾病并避免使用皮质类固醇。
更新日期:2019-11-01
down
wechat
bug